Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

33.95
-0.2190-0.64%
Volume:4K
Turnover:125.42K
Market Cap:13.58M
PE:- -
High:34.04
Open:34.00
Low:33.95
Close:34.17
52wk High:34.86
52wk Low:25.79
Shares:400.00K
Float Shares:400.00K
Volume Ratio:8.23
T/O Rate:0.92%
Dividend:0.08
Dividend Rate:0.24%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)

TIPRANKS
·
Sep 15

Bio-Techne Supplements Merger Proxy Amid Shareholder Litigation

TIPRANKS
·
Sep 15

Contineum Therapeutics Says Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint

MT Newswires Live
·
Sep 15

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 15

Niki BioSolutions Highlights Strategic Synergies in Alzheimer’s Diagnostics

TIPRANKS
·
Sep 15

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 15

Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint

Dow Jones
·
Sep 15

Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal

Reuters
·
Sep 15

Contineum Therapeutics, - Johnson & Johnson Continues to Evaluate Trial Data for Jnj-5120/Pipe-307

THOMSON REUTERS
·
Sep 15

Merck & Co Exec Says Potential 340B and Policy Evolutions Would Create Tailwinds but are not Material to the Business - Morgan Stanley Conf

THOMSON REUTERS
·
Sep 15

Merck & Co Exec Says Timing for Raising the $70 Bln Forecast is "to be Determined" Adds "It's Coming"

THOMSON REUTERS
·
Sep 15

Biofrontera announces FDA approval of Ameluz supplemental new drug application

TIPRANKS
·
Sep 14

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

J&J - Jnj Reports Rybrevant Plus Chemotherapy Extends Pfs2 by 10.8 Months in Nsclc

THOMSON REUTERS
·
Sep 14

Johnson & Johnson’s Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Mutation-Positive Lung Cancer

THOMSON REUTERS
·
Sep 14

J&J - Jnj Reports no New Safety Signals for Rybrevant Plus Chemotherapy in Nsclc Study

THOMSON REUTERS
·
Sep 14

Scholar Rock Wins FDA Approval for SMA Therapy

TIPRANKS
·
Sep 14

Potential Buyer Emerges for Johnson & Johnson's Orthopedics Unit

Deep News
·
Sep 14

Scholar Rock price target raised to $84 from $76 at BMO Capital

TIPRANKS
·
Sep 14